The highlight of Probiodrug’s FY17 results presentation was the rather detailed introduction of the Phase IIb development programme for the lead asset PQ912, a small molecule inhibitor of glutaminyl cyclase (QC) for Alzheimer’s disease (AD) patients. Two Phase IIb trials (in Europe and the US) are designed to gather the amount of data that, if sufficiently positive, could allow for accelerated or conditional regulatory approval. The first Phase IIb study in Europe is expected to s
13 Apr 2018
Emerging details of PQ912 late-stage development
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Emerging details of PQ912 late-stage development
Vivoryon Therapeutics N.V. (VVY:AMS) | 0 0 0.0%
- Published:
13 Apr 2018 -
Author:
Dr Jonas Peciulis -
Pages:
6
The highlight of Probiodrug’s FY17 results presentation was the rather detailed introduction of the Phase IIb development programme for the lead asset PQ912, a small molecule inhibitor of glutaminyl cyclase (QC) for Alzheimer’s disease (AD) patients. Two Phase IIb trials (in Europe and the US) are designed to gather the amount of data that, if sufficiently positive, could allow for accelerated or conditional regulatory approval. The first Phase IIb study in Europe is expected to s